BioSpace News Archive

Teva Pharmaceutical Industries Ltd. announced that President & CEO Kåre Schultz will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday January 13, 2020.

New “personal heart health coach” mobile app will pair with award-winning offerings that have set a new standard for personal heart health technology

585 transplants were performed at Tampa General Hospital in 2019, eclipsing the hospital’s previous total and placing it among the busiest organ transplant centers in the nation

Mundipharma has announced that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife®.

ContraFect Corporation announced that Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect will present an update on the recently initiated pivotal Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis, and a general corporate overview at the Biotech Showcase on Monday, January 13, 2020, at 2:30 PM PT in San Francisco, CA..

Tampa General Hospital is the first in Florida to adopt and use special machines that allow donor hearts, lungs and livers to function outside a human body

Transgene and NEC Corporation announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, a therapeutic vaccine based on the myvac™ technology and powered by NEC’s cutting-edge AI capabilities.

InxMed Co., Ltd. announced that the company has entered into a clinical collaboration with a subsidiary of Merck & Co, Inc. Kenilworth, NJ U.S.A., known as MSD outside the United States and Canada, to evaluate IN10018, an investigational proprietary focal adhesion kinase inhibitor in combination with pembrolizumab, MSD’s anti-PD-1 therapy, in patients with pancreatic cancer.

Rite Aid Corporation announced that it has commenced an offer to exchange up to $600 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2023 for newly issued 7.500% Senior Secured Notes due 2025, upon the terms and subject to the conditions set forth in the offering memorandum dated January 6, 2020.

From machines that develop human skills, to intelligent factory automation, personal health devices and social solutions, OMRON shows CES attendees how it is building a better tomorrow [06-January-2020] HOFFMAN ESTATES, Ill. , Jan. 6, 2020 /PRNewswire/ -- Global technology leader OMRON Corporation is showcasing the largest range of its technology at the 2020 Cons